Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition

Journal of Cellular Biochemistry

Volumn 118, Issue 12, 2017, Pages 4639-4651

  Hsieh, Yei San ^a   Liao, Chiung Ho ^b   Chen, Wan Shen ^c   Pai, Jih Tung ^a   Weng, Meng Shih ^c  

^a TAO YUAN GENERAL HOSPITAL   (Taiwan)

^b Ministry of Health and Welfare   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

c Met; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); EPITHELIAL TO MESENCHYMAL TRANSITION (EMT); HEPATOCYTE GROWTH FACTOR (HGF); SHIKONIN

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SCATTER FACTOR; SHIKONIN; UVOMORULIN; VIMENTIN; NAPHTHOQUINONE; SCATTER FACTOR RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LITHOSPERMUM; LITHOSPERMUM ERYTHRORHIZON; LUNG CANCER; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; A-549 CELL LINE; CELL MOTION; DRUG EFFECT; ENZYMOLOGY; GENETICS; LUNG TUMOR; MAPK SIGNALING; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY;

A549 CELLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 85020534794     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26128     Document Type: Article

References (50)

1. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N. 2006. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290:C1532–C1542.
2. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. 2008. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99:1476–1483.
3. Arteaga C. 2003. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 30:3–14.
4. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, Salgia R. 2004. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res 24:1031–1038.
5. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925.
6. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629–641.
7. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, Menendez S, Zazo S, Domine M, Salido M, Mojal S, Garcia de Herreros A, Rovira A, Albanell J, Arriola E. 2014a. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 20:938–950.
8. Canadas I, Taus A, Gonzalez I, Villanueva X, Gimeno J, Pijuan L, Domine M, Sanchez-Font A, Vollmer I, Menendez S, Arpi O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E. 2014b. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget 5:5246–5256.
9. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. 2012. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 11:660–669.
10. Chen QY, Jiao DM, Wu YQ, Chen J, Wang J, Tang XL, Mou H, Hu HZ, Song J, Yan J, Wu LJ, Wang Z. 2016. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/ Akt/mTOR pathway. Oncotarget 7:18247–18261.
11. Chen X, Yang L, Oppenheim JJ, Howard MZ. 2002. Cellular pharmacology studies of shikonin derivatives. Phytother Res 16:199–209.
12. Chen Y, Zheng L, Liu J, Zhou Z, Cao X, Lv X, Chen F. 2014. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int Immunopharmacol 21:447–455.
13. Chien MH, Ying TH, Hsieh YS, Chang YC, Yeh CM, Ko JL, Lee WS, Chang JH, Yang SF. 2012. Dioscorea nipponica Makino inhibits migration and invasion of human oral cancer HSC-3 cells by transcriptional inhibition of matrix metalloproteinase-2 through modulation of CREB and AP-1 activity. Food Chem Toxicol 50:558–566.
14. Comoglio PM, Boccaccio C. 2001. Scatter factors and invasive growth. Semin Cancer Biol 11:153–165.
15. Davidson MR, Gazdar AF, Clarke BE. 2013. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 5 Suppl 5:S463–S478.
16. De Craene B, Berx G. 2013. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110.
17. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043.
18. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. 2003. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807.
19. Hong D, Jang SY, Jang EH, Jung B, Cho IH, Park MJ, Jeong SY, Kim JH. 2015. Shikonin as an inhibitor of the LPS-induced epithelial-to-mesenchymal transition in human breast cancer cells. Int J Mol Med 36:1601–1606.
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69–90.
21. Jiang W, Hiscox S, Matsumoto K, Nakamura T. 1999. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29:209–248.
22. Kao SJ, Su JL, Chen CK, Yu MC, Bai KJ, Chang JH, Bien MY, Yang SF, Chien MH. 2012. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Toxicol Appl Pharmacol 261:105–115.
23. Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. 2013. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 7:1093–1102.
24. Kim IH, Lee IH, Lee JE, Hong SH, Kim TJ, Lee KY, Kim YK, Kim SJ, Sung SW, Park JK, Yoo IR, Kim YS, Kim JO, Kang JH. 2016. Prognostic impact of multiple clinicopathologic risk factors and c-MET overexpression in patients who have undergone resection of stage IB non-small-cell lung cancer. Clin Lung Cancer 17:e31–e43.
25. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792.
26. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. 2004. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923.
27. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665–7670.
28. Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC, Kim CH. 2012. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol 48:1114–1119.
29. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. 2011. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 17:472–482.
30. Liu J, Wang S, Zhang Y, Fan HT, Lin HS. 2015. Traditional Chinese medicine and cancer: History, present situation, and development. Thorac Cancer 6:561–569.
31. Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, Li S, Wen G, Dong W, Wang X, Dou QP, Liu J. 2011. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol 658:242–247.
32. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. 2007. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67:2081–2088.
33. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. 2002. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8:620–627.
34. Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C, Chenping Z. 2008. Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res 22:407–415.
35. Min R, Zun Z, Min Y, Wenhu D, Wenjun Y, Chenping Z. 2011. Shikonin inhibits tumor invasion via down-regulation of NF-kappaB-mediated MMP-9 expression in human ACC-M cells. Oral Dis 17:362–369.
36. Ogunwobi OO, Liu C. 2011. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 28:721–731.
37. Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. 2014. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther 7:969–983.
38. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. 2006. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839–844.
39. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ. 1997. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57:433–439.
40. Singh F, Gao D, Lebwohl MG, Wei H. 2003. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett 200:115–121.
41. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890.
42. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. 2005. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455–9462.
43. Tian R, Li Y, Gao M. 2015. Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR-NF-kappaB signalling pathway in human epidermoid carcinoma A431 cells. Biosci Re 35:e00189.
44. Trusolino L, Comoglio PM. 2002. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289–300.
45. Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H. 2012. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 32:3251–3258.
46. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. 2011. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6:2011–2017.
47. Yin SY, Peng AP, Huang LT, Wang YT, Lan CW, Yang NS. 2013. The Phytochemical Shikonin Stimulates Epithelial-Mesenchymal Transition (EMT) in Skin Wound Healing. Evid Based Complement Alternat Med 2013:262796.
48. Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS. 2014. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J Agric Food Chem 62:2085–2095.
49. Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck E. 2012. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 11:503–513.
50. Zhao Q, Kretschmer N, Bauer R, Efferth T. 2015. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Int J Cancer 137:1446–1456.